Licensing status

Publication and contact information

Assays & screens

Ligand-based, receptor-capturing (LRC) technology to identify cell surface receptors of therapeutic or pathologic ligands

LRC technology could be used to identify cell surface receptor targets of ligands. The technology uses a chemoreactive reagent that contains a glycosylated cell surface-binding moiety, a biotin tag and an amino-reactive moiety, which binds to a ligand of interest. In cell culture or tissue, the ligand-bound chemoreactive agent attached to the ligand's cell surface receptor and the biotin tag was used to purify the receptor for identification using mass spectroscopy. In various cells, receptors for ligands, including insulin and transferrin, were identified. In cell culture, the LRC technology identified five surface-binding proteins for vaccinia virus, which were verified using small interfering RNA-mediated knockout of the receptors. Next steps include using the platform for drug development.

SciBX 5(39); doi:10.1038/scibx.2012.1038
Published online Oct. 4, 2012

Patent application filed; available for licensing

Frei, A.P. et al. Nat. Biotechnol.; published online Sept. 16, 2012;
Contact: Bernd Wollscheid, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland